Journey Medical Corp (DERM): Long-Term Debt
$25.28M
As of 2025-12-31
$25.47M
As of 2026-06-30
-3.1%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.28M | +1.6% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $24.88M | +70.1% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $14.62M | -47.3% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $27.77M | n/a | 2024-03-29, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Journey Medical Corp (DERM) | 2025-12-31 | $25.28M | +1.6% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $47.21M | n/a |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $52.42M | -9.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $9.70M | +1.9% |
| Eton Pharmaceuticals, Inc. (ETON) | 2024-12-31 | $29.81M | n/a |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $45.00M | 0.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $96.37M | n/a |
| Standard Biotools Inc. (LAB) | 2024-12-31 | $299.0K | -99.5% |
| Cytokinetics Inc (CYTK) | 2024-12-31 | $619.52M | -3.1% |
Compare DERM, NUVB, FBIO, KURA side by side · Screen every company in Pharmaceutical Preparations ↗